NCT06274541Completed
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The t-BRCA Study
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
A pilot study to evaluate the feasibility of a NGS-based tumour BRCA1/2 mutation testing pathway initiated in the oncology clinic for patients with HGSEC, either at primary diagnosis or first relapse, whereby only patients with a positive germline BRCA1/2 mutation test will be referred to clinical genetics.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 200 (actual)
- First submitted
- 6 Jun 2019
- Start date
- 22 Mar 2019
- Primary completion date
- 17 Dec 2025
- Lead sponsor
- Cancer Trials Ireland
- Diseases
- Ovarian cancer
- NCT number
- NCT06274541
What you commit to
- Study type: Observational
- Participants enrolled: 200
- From 22 Mar 2019 to the primary completion date, 17 Dec 2025
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have been previously tested for germline BRCA1/2 mutations or have been tested with a hereditary cancer gene panel.
Other illness
- Patients in second or later relapse of their disease
Other
- Patients with non-high grade serous or non-high grade endometrioid ovarian, fallopian tube or primary peritoneal carcinoma or unclear histology
- Patients who are known BRCA1 or BRCA2 mutation carriers
Who the study is looking for
- Patients with high grade serous or high grade endometrioid ovarian, fallopian tube or primary peritoneal carcinoma who:
- Are newly diagnosed FIGO stage I - IV or Are currently undergoing primary chemotherapy +/- surgery or Are in remission after completing primary treatment for FIGO stage I - IV disease or Are being planned for, are undergoing or have completed treatment for first relapse
- Patients with available tumour tissue (archival FFPE surgical resection or tissue/peritoneal biopsy) obtained prior to chemotherapy delivery, for tumour BRCA1/2 testing
- Patients able to give signed and written informed consent
- Patients aged 18 years and above
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cork University Hospital Coordinator of this site? Confirm its status | Cork | Ireland | Unknown status |
| Bon Secours Coordinator of this site? Confirm its status | Cork | Ireland | Unknown status |
| Mater Misericordiae University Hospital / Mater Private Hospital Coordinator of this site? Confirm its status | Dublin | Ireland | Unknown status |
| St. James's Hospital Coordinator of this site? Confirm its status | Dublin | Ireland | Unknown status |
| University Hospital Limerick Coordinator of this site? Confirm its status | Limerick | Ireland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.